PharmAbcine focuses on Ab therapeutics pipeline in oncology

July 3, 2020 | Friday | News

Signs long-term contract manufacturing organization ggreement for Olinvacimab with Binex

Image credit- shutterstock.com

South Korea based PharmAbcine, a biotech company focusing on the development of antibody therapeutics, announced that it has signed a contract manufacturing organization (CMO) agreement with biologics contract development and manufacturing organization (CDMO) Binex for additional production of investigational Olinvacimab (TTAC-0001), PharmAbcine's leading antibody (Ab) therapeutics pipeline in oncology.

Under the agreement, Binex is responsible for large-scale manufacturing of clinical investigational material for PharmAbcine for its global Phase 2 trials on olinvacimab + immunotherapy combination for metastatic triple negative breast cancer (the U.S. included) and trials on various common solid tumors. Binex has been a clinical manufacturing partner of PharmAbcine since early global clinical trials on olinvacimab.

Olinvacimab, an anti-vascular endothelial growth factor receptor 2 (VEGFR2), targets and inhibits tumor angiogenesis-inducing VEGFR2. PharmAbcine is conducting a Phase 2 clinical trial on olinvacimab in patients with Avastin-refractory rGBM in the U.S. and Australia. In addition, Phase 1b trials on olinvacimab plus PD-1 antibody Keytruda (pembrolizumab) combination for rGBM and mTNBC are still going on in Australia in collaboration with MSD (Merck).

Sign up for the editor pick and get articles like this delivered right to your inbox.

Comments

Podcast

APAC's Alliance-Driven Biotech Boom
31 May 2025
Upskilling and flexibility are key to staying relevant as hiring grows
31 May 2025
“APAC faces a disproportionate burden of vision impairment”
31 May 2025
“APAC now leads global clinical development of multi-specific antibodies, accounting for over 40% of trials”
31 May 2025